2,951 research outputs found

    Sediment identification using free fall penetrometer acceleration-time histories

    Get PDF
    Abstract Knowledge of physical properties of near-surface sediments is an important requirement for many studies of the seafloor. Dynamic or Free Fall Penetrometers (FFP), instrumented with accelerometers, are widely used to assess the mechanical properties of the sediment by deriving penetration resistance from the deceleration response of the probe as it impacts and embeds the seabed. Other field investigations, a priori knowledge or a very basic description of the type of sediment (such as a description of the sediment as soft, medium or hard) derived from studying the deceleration response (accelerometer-time histories) are used for sediment identification prior to the application of an appropriate strength determination model. In many cases this information is site-specific and in others the penetration resistance is overestimated due to the dilatory effects observed in sediment with an undetected grain fraction. In this study variables affecting a dynamic penetrometer-sediment interaction system are identified. Using data from field investigations and literature we found a relationship among five variables: peak acceleration, embedment depth, total embedment time, velocity of impact and grain size. This is used to formulate a sediment identification model. The model accounts for variables that may vary widely within one deployment and it can be applied to other FFPs with different physical characteristics (such as a different mass or size). This may lead to the increased use of FFP as a deployment tool for rapid in situ characterization of the seafloor

    In Solidarity

    Full text link
    This edition of Next Page is a departure from our usual question and answer format with a featured campus reader. Instead, we asked speakers who participated in the College’s recent Student Solidarity Rally (March 1, 2017) to recommend readings that might further our understanding of the topics on which they spoke

    Updated fracture incidence rates for the US version of FRAX®

    Get PDF
    # The Author(s) 2009. This article is published with open access at Springerlink.com Summary On the basis of updated fracture and mortality data, we recommend that the base population values used in the US version of FRAX ® be revised. The impact of suggested changes is likely to be a lowering of 10-year fracture probabilities. Introduction Evaluation of results produced by the US version of FRAX ® indicates that this tool overestimates the likelihood of major osteoporotic fracture. In an attempt to correct this, we updated underlying fracture and mortality rates for the model. Methods We used US hospital discharge data from 2006 t

    A Sweeping Jet Application on a High Reynolds Number Semispan Supercritical Wing Configuration

    Get PDF
    The FAST-MAC circulation control model was modified to test an array of unsteady sweeping-jet actuators at realistic flight Reynolds numbers in the National Transonic Facility at the NASA Langley Research Center. Two types of sweeping jet actuators were fabricated using rapid prototype techniques, and directed over a 15% chord simple-hinged flap. The model was configured for low-speed high-lift testing with flap deflections of 30 deg and 60 deg, and a transonic cruise configuration having a 0 deg flap deflection. For the 30 deg flap high-lift configuration, the sweeping jets achieved comparable lift performance in the separation control regime, while reducing the mass flow by 54% as compared to steady blowing. The sweeping jets however were not effective for the 60 deg flap. For the transonic cruise configuration, the sweeping jets reduced the drag by 3.3% at an off-design condition. The drag reduction for the design lift coefficient for the sweeping jets offer is only half the drag reduction shown for the steady blowing case (6.5%), but accomplished this with a 74% reduction in mass flow

    Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction - REVEAL: A randomized controlled trial

    Get PDF
    Context: Acute ST-segment elevation myocardial infarction (STEMI) is a leading cause of morbidity and mortality. In experimental models of MI, erythropoietin reduces infarct size and improves left ventricular (LV) function. Objective: To evaluate the safety and efficacy of a single intravenous bolus of epoetin alfa in patients with STEMI. Design, Setting, and Patients: A prospective, randomized, double-blind, placebo-controlled trial with a dose-escalation safety phase and a single dose (60 000 U of epoetin alfa) efficacy phase; the Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction (REVEAL) trial was conducted at 28 US sites between October 2006 and February 2010, and included 222 patients with STEMI who underwent successful percutaneous coronary intervention (PCI) as a primary or rescue reperfusion strategy. Intervention: Participants were randomly assigned to treatment with intravenous epoetin alfa or matching saline placebo administered within 4 hours of reperfusion. Main Outcome Measure: Infarct size, expressed as percentage of LV mass, assessed by cardiac magnetic resonance (CMR) imaging performed 2 to 6 days after study medication administration (first CMR) and again 12±2 weeks later (second CMR). Results: In the efficacy cohort, the infarct size did not differ between groups on either the first CMR scan (n=136; 15.8% LV mass [95% confidence interval {CI}, 13.3-18.2% LV mass] for the epoetin alfa group vs 15.0% LV mass [95% CI, 12.6-17.3% LV mass] for the placebo group; P=.67) or on the second CMR scan (n=124; 10.6% LV mass [95% CI, 8.4-12.8% LV mass] vs 10.4% LV mass [95% CI, 8.5-12.3% LV mass], respectively; P=.89). In a prespecified analysis of patients aged 70 years or older (n=21), the mean infarct size within the first week (first CMR) was larger in the epoetin alfa group (19.9% LV mass; 95% CI, 14.0-25.7% LV mass) than in the placebo group (11.7% LV mass; 95% CI, 7.2-16.1% LV mass) (P=.03). In the safety cohort, of the 125 patients who received epoetin alfa, the composite outcome of death, MI, stroke, or stent thrombosis occurred in 5 (4.0%; 95% CI, 1.31%-9.09%) but in none of the 97 who received placebo (P=.04). Conclusions: In patients with STEMI who had successful reperfusion with primary or rescue PCI, a single intravenous bolus of epoetin alfa within 4 hours of PCI did not reduce infarct size and was associated with higher rates of adverse cardiovascular events. Subgroup analyses raised concerns about an increase in infarct size among older patients. Trial Registration: clinicaltrials.gov Identifier: NCT00378352. ©2011 American Medical Association. All rights reserved
    • …
    corecore